IGMS Quote, Financials, Valuation and Earnings

BioXcel Therapeutics has a net margin of -8894.9% compared to IGM Biosciences's net margin of -6378.51%. IGM Biosciences's return on equity of -159.45% beat BioXcel Therapeutics's return on equity of --.

IGM Biosciences has a consensus price target of $1.88, signalling upside risk potential of 65.93%. On the other hand BioXcel Therapeutics has an analysts' consensus of $48.00 which suggests that it could grow by 2269.28%. Given that BioXcel Therapeutics has higher upside potential than IGM Biosciences, analysts believe BioXcel Therapeutics is more attractive than IGM Biosciences.

IGM Biosciences has a beta of 0.610, which suggesting that the stock is 38.975% less volatile than S&P 500. In comparison BioXcel Therapeutics has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.161%.

IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioXcel Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. BioXcel Therapeutics pays out -- of its earnings as a dividend.

IGM Biosciences quarterly revenues are $412K, which are larger than BioXcel Therapeutics quarterly revenues of $214K. IGM Biosciences's net income of -$36.6M is lower than BioXcel Therapeutics's net income of -$13.7M. Notably, IGM Biosciences's price-to-earnings ratio is -- while BioXcel Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 25.52x versus 1.71x for BioXcel Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -8894.9% compared to IGM Biosciences's net margin of -49.65%. IGM Biosciences's return on equity of -159.45% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

IGM Biosciences has a consensus price target of $1.88, signalling upside risk potential of 65.93%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that IGM Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe IGM Biosciences is more attractive than NovaBay Pharmaceuticals.

IGM Biosciences has a beta of 0.610, which suggesting that the stock is 38.975% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

IGM Biosciences quarterly revenues are $412K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IGM Biosciences's net income of -$36.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, IGM Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 25.52x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -8894.9% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -159.45% beat Oragenics's return on equity of --.

IGM Biosciences has a consensus price target of $1.88, signalling upside risk potential of 65.93%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 493.12%. Given that Oragenics has higher upside potential than IGM Biosciences, analysts believe Oragenics is more attractive than IGM Biosciences.

IGM Biosciences has a beta of 0.610, which suggesting that the stock is 38.975% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

IGM Biosciences quarterly revenues are $412K, which are larger than Oragenics quarterly revenues of --. IGM Biosciences's net income of -$36.6M is lower than Oragenics's net income of -$3.3M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 25.52x versus 1.05x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -8894.9% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -159.45% beat Theriva Biologics's return on equity of --.

IGM Biosciences has a consensus price target of $1.88, signalling upside risk potential of 65.93%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 1032.29%. Given that Theriva Biologics has higher upside potential than IGM Biosciences, analysts believe Theriva Biologics is more attractive than IGM Biosciences.

IGM Biosciences has a beta of 0.610, which suggesting that the stock is 38.975% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

IGM Biosciences quarterly revenues are $412K, which are larger than Theriva Biologics quarterly revenues of --. IGM Biosciences's net income of -$36.6M is lower than Theriva Biologics's net income of -$4.4M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 25.52x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.